Table 2.
Univariate and multivariate analyses for overall mortality.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |
| Age | 1.09 | 1.07–1.12 | 1.05 | 1.02–1.08 |
| Sex | 0.97 | 0.77–1.37 | ||
| High blood pressure | 1.02 | 0.76–1.77 | ||
| Diabetes mellitus | 1.27 | 1.01–1.60 | 1.36 | 1.07–1.72 |
| Hyperlipidemia | 1.10 | 0.87–1.38 | ||
| Chronic lung disease | 1.30 | 0.98–1.71 | ||
| Stroke/TIA | 1.17 | 0.87–1.57 | ||
| GFR | 0.99 | 0.98–0.99 | 0.99 | 0.98–0.99 |
| Functional disability | 0.40 | 0.26–0.61 | 1.28 | 1.04–1.58 |
| Ischemic LV dysfunction | 1.35 | 1.05–1.73 | ||
| Previous HF admission | 1.32 | 1.06–1.66 | ||
| QRS > 120 ms | 0.84 | 0.64–1.11 | ||
| No sinus rhythm | 1.22 | 0.98–1.54 | 1.33 | 1.06–1.68 |
| LVEF | 0.99 | 0.98–1.00 | ||
| LVEF improvement | 0.48 | 0.36–0.62 | 0.49 | 0.37–0.64 |
| NYHA class III–IV | 1.26 | 0.92–1.74 | ||
| Beta-blockers | 0.53 | 0.41–0.67 | 0.62 | 0.48–0.80 |
| ARNI | 0.27 | 0.16–0.44 | 0.36 | 0.21–0.61 |
| ACEi/ARB | 0.88 | 0.70–1.10 | ||
| MRA | 1.09 | 0.83–1.44 | ||
| SGLT2i | 0.12 | 0.03–0.50 | ||
| ICD/CRT | 0.53 | 0.35–0.82 | ||
Included variables in the multivariate analysis: age, GFR, diabetes, previous HF, sinus rhythm, QRS duration, functional disability, ACEi/ARBs, beta-blocker, MRA, ARNI, SGLT2i, digoxin, anticoagulation, LVEF improvement and ICD/CRT. ACEi: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, CRT: cardiac resynchronization therapy, GFR: glomerular filtration rate, HF: heart failure, ICD: implantable cardioverter defibrillator, LV: left ventricle, LVEF: left ventricular ejection fraction, MRA: mineralocorticoid receptor antagonist, SGLT2i: sodium-glucose cotransporter 2 inhibitors, NYHA: New York Heart Association, TIA: transient ischemic attack. Statistically significant variables are indicated in bold.